Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMLX Amylyx Pharmaceuticals	$8.34 +0.7%	$5.88	$1.76 ▼ $8.59	$743.44M	-0.49	1.15 million shs	1.13 million shs
AVBP ArriVent BioPharma	$22.05 -2.9%	$21.91	$15.47 ▼ $36.37	$754.39M	1.2	235,563 shs	316,541 shs
GNFT GENFIT	$3.82 -0.4%	$4.04	$2.55 ▼ $6.42	$189.51M	1.08	10,314 shs	603 shs
IMTX Immatics	$6.00 -3.4%	$5.58	$3.30 ▼ $13.09	$729.30M	0.81	683,311 shs	187,803 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMLX Amylyx Pharmaceuticals	0.00%	+8.59%	+63.53%	+109.55%	+293.40%
AVBP ArriVent BioPharma	0.00%	+1.94%	-11.41%	+21.55%	+12.21%
GNFT GENFIT	0.00%	+4.52%	-5.00%	+9.47%	-17.60%
IMTX Immatics	0.00%	+0.50%	+2.56%	+40.85%	-51.18%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMLX Amylyx Pharmaceuticals	3.2733 of 5 stars	4.5	1.0	2.5	2.5	0.6
AVBP ArriVent BioPharma	2.3834 of 5 stars	4.6	0.0	2.9	0.8	0.0
GNFT GENFIT	2.2957 of 5 stars	3.5	5.0	0.0	0.0	0.0
IMTX Immatics	3.071 of 5 stars	3.6	4.0	3.5	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMLX Amylyx Pharmaceuticals	3.00	Buy	$11.75	40.89% Upside
AVBP ArriVent BioPharma	3.14	Buy	$39.29	78.17% Upside
GNFT GENFIT	3.00	Buy	$13.00	240.76% Upside
IMTX Immatics	3.20	Buy	$14.67	144.44% Upside

Current Analyst Ratings Breakdown

Latest GNFT, AMLX, AVBP, and IMTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	AMLX Amylyx Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$10.00
7/10/2025	AVBP ArriVent BioPharma	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy	$33.00
6/24/2025	AMLX Amylyx Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold
6/24/2025	AMLX Amylyx Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
6/24/2025	AMLX Amylyx Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$17.00
6/24/2025	AVBP ArriVent BioPharma	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$39.00 ➝ $44.00
6/24/2025	AVBP ArriVent BioPharma	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$45.00
6/17/2025	AMLX Amylyx Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
5/30/2025	AMLX Amylyx Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/28/2025	IMTX Immatics	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$10.00
5/20/2025	AVBP ArriVent BioPharma	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$40.00

(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMLX Amylyx Pharmaceuticals	$87.37M	8.51	N/A	N/A	$2.40 per share	3.48
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	$7.65 per share	N/A
GNFT GENFIT	$76.77M	2.48	$0.07 per share	54.19	$1.50 per share	2.54
IMTX Immatics	$168.65M	4.32	$0.24 per share	24.56	$5.12 per share	1.17

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMLX Amylyx Pharmaceuticals	-$301.74M	-$3.11	N/A	N/A	N/A	N/A	-77.21%	-63.84%	8/6/2025 (Estimated)
AVBP ArriVent BioPharma	-$80.49M	-$3.77	N/A	N/A	N/A	N/A	-49.21%	-46.61%	8/13/2025 (Estimated)
GNFT GENFIT	$1.63M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/24/2025 (Estimated)
IMTX Immatics	$16.47M	-$0.17	N/A	N/A	N/A	-14.73%	-4.52%	-3.34%	8/12/2025 (Estimated)

Latest GNFT, AMLX, AVBP, and IMTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	AMLX Amylyx Pharmaceuticals	-$0.43	N/A	N/A	N/A	N/A	N/A
8/13/2025	Q2 2025	AVBP ArriVent BioPharma	-$0.70	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q1 2025	IMTX Immatics	-$0.38	N/A	N/A	N/A	$13.05 million	N/A
5/13/2025	Q1 2025	IMTX Immatics	-$0.39	-$0.35	+$0.04	-$0.35	$14.92 million	$20.12 million
5/12/2025	Q1 2025	AVBP ArriVent BioPharma	-$0.66	-$1.90	-$1.24	-$1.90	N/A	N/A
5/8/2025	Q1 2025	AMLX Amylyx Pharmaceuticals	-$0.45	-$0.42	+$0.03	-$0.42	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMLX Amylyx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	N/A
GNFT GENFIT	N/A	N/A	N/A	N/A	N/A
IMTX Immatics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMLX Amylyx Pharmaceuticals	N/A	12.05	12.05
AVBP ArriVent BioPharma	N/A	14.34	14.34
GNFT GENFIT	0.08	1.23	1.23
IMTX Immatics	N/A	10.28	10.28

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMLX Amylyx Pharmaceuticals	95.84%
AVBP ArriVent BioPharma	9.48%
GNFT GENFIT	2.24%
IMTX Immatics	64.41%

Insider Ownership

Company	Insider Ownership
AMLX Amylyx Pharmaceuticals	11.70%
AVBP ArriVent BioPharma	18.58%
GNFT GENFIT	4.20%
IMTX Immatics	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMLX Amylyx Pharmaceuticals	200	89.14 million	78.71 million	Optionable
AVBP ArriVent BioPharma	40	34.21 million	27.86 million	N/A
GNFT GENFIT	120	50.00 million	47.90 million	Not Optionable
IMTX Immatics	260	121.55 million	N/A	Optionable

GNFT, AMLX, AVBP, and IMTX Headlines

Recent News About These Companies

Immatics N.V. (NASDAQ:IMTX) Receives Consensus Recommendation of "Buy" from Brokerages

July 17 at 4:09 AM | marketbeat.com

Immatics (NASDAQ:IMTX) Shares Up 2.9% - What's Next?

July 17 at 3:25 AM | marketbeat.com

Here Is What You Need To Know Before Investing In Immatics N.V. (IMTX)

July 9, 2025 | insidermonkey.com

Immatics N.V. (IMTX) Earnings Surprise Summary (EPS) - Seeking Alpha

June 26, 2025 | seekingalpha.com

Immatics N.V. (NASDAQ:IMTX) Given Average Rating of "Buy" by Brokerages

June 22, 2025 | marketbeat.com

Immatics N.V. Shareholders Approve Key Resolutions at June 2025 AGM

June 18, 2025 | tipranks.com

Immatics: Taking Off On A PRAME Rocketship

June 4, 2025 | seekingalpha.com

Does Immatics (IMTX) Have the Potential to Rally 174.54% as Wall Street Analysts Expect?

June 3, 2025 | zacks.com

Immatics rises on data from early stage cell therapy trial

June 2, 2025 | msn.com

Immatics Presents Promising IMA203 Data at ASCO 2025

June 2, 2025 | tipranks.com

Immatics (IMTX) Shares Promising Data from IMA203 Melanoma Trials | IMTX Stock News

June 1, 2025 | gurufocus.com

Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to ...

May 31, 2025 | gurufocus.com

Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to ...

May 31, 2025 | gurufocus.com

Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to ...

May 31, 2025 | gurufocus.com

Immatics N.V. Reports Promising Long-Term Efficacy and Safety Data from Phase 1b Trial of IMA203 PRAME Cell Therapy in Metastatic Melanoma

May 31, 2025 | quiverquant.comQ

Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma

May 31, 2025 | globenewswire.com

Deutsche Bank Initiates Coverage of Immatics N.V. (IMTX) with Buy Recommendation

May 29, 2025 | msn.com

Immatics (IMTX) Gets a Buy from Bank of America Securities

May 16, 2025 | theglobeandmail.com

We're Hopeful That Immatics (NASDAQ:IMTX) Will Use Its Cash Wisely

May 15, 2025 | finance.yahoo.com

Immatics Reports Increased Q1 2025 Loss Amid Rising R&D Costs

May 13, 2025 | tipranks.com

Immatics Announces First Quarter 2025 Financial Results and Business Update

May 13, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNFT, AMLX, AVBP, and IMTX Company Descriptions

Amylyx Pharmaceuticals NASDAQ:AMLX

$8.34 +0.06 (+0.72%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$8.39 +0.05 (+0.60%)

As of 07/18/2025 07:03 PM Eastern

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

ArriVent BioPharma NASDAQ:AVBP

$22.05 -0.67 (-2.95%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$22.17 +0.12 (+0.54%)

As of 07/18/2025 04:31 PM Eastern

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

GENFIT NASDAQ:GNFT

$3.82 -0.02 (-0.39%)

As of 07/18/2025 03:58 PM Eastern

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

Immatics NASDAQ:IMTX

$6.00 -0.21 (-3.38%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$5.86 -0.15 (-2.42%)

As of 07/18/2025 07:56 PM Eastern

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time